Description
P23 BETRIXABAN: IMPACT ON ROUTINE AND SPECIFIC COAGULATION ASSAYS – A PRACTICAL LABORATORY GUIDE
- You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart
Article: P23 BETRIXABAN: IMPACT ON ROUTINE AND SPECIFIC COAGULATION ASSAYS – A PRACTICAL LABORATORY GUIDE
€3.03
